Page last updated: 2024-10-24

determination of left/right asymmetry in lateral mesoderm

Definition

Target type: biologicalprocess

The establishment of the lateral mesoderm with respect to the left and right halves. [GOC:mtg_heart]

The establishment of left-right asymmetry in the lateral mesoderm is a complex process driven by intricate molecular signaling pathways. It involves a cascade of events, beginning with the formation of a signaling center on the left side of the embryo called the "node." The node is characterized by the presence of cilia, hair-like structures that rotate in a clockwise direction, generating a leftward fluid flow. This fluid flow is crucial for the asymmetric activation of downstream signaling pathways.

The leftward flow of fluid activates a signaling pathway involving Nodal, a TGF-beta family member. Nodal, expressed on the left side of the node, is transported by the fluid flow, promoting its accumulation on the left side of the embryo. Nodal activates downstream targets, including Lefty2 and Pitx2, which are crucial for the development of left-sided structures.

Simultaneously, the right side of the embryo expresses a different set of genes, including FGF8 and Shh, which establish a distinct signaling center. This right-sided signaling center inhibits Nodal activity on the right side of the embryo, contributing to the establishment of left-right asymmetry.

The asymmetric distribution of Nodal signaling creates a molecular gradient, with high concentrations of Nodal on the left side and lower concentrations on the right. This gradient influences the development of various organs, such as the heart, lungs, and gut, ensuring their correct positioning and function. For instance, the heart develops on the left side of the body, while the liver develops on the right.

The determination of left-right asymmetry in the lateral mesoderm is therefore a tightly regulated process involving intricate molecular signaling pathways and physical cues. This process is essential for the proper development and function of various organs in the body.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Smoothened homologA protein smoothened that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99835]Homo sapiens (human)
Sonic hedgehog proteinA sonic hedgehog protein that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15465]Homo sapiens (human)

Compounds (17)

CompoundDefinitionClassesRoles
jervinejervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structurepiperidines
cyclopaminepiperidinesglioma-associated oncogene inhibitor
pd 173955PD 173955: inhibits src family-selective tyrosine kinase; structure in first sourcearyl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine
tyrosine kinase inhibitor
purmorphaminepurmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group.

purmorphamine: structure in first source
aromatic ether;
morpholines;
purines;
secondary amino compound
osteogenesis regulator;
SMO receptor agonist
cur 61414CUR 61414: inhibits the hedehog signaling pathway; structure in first source
abt 869aromatic amine;
indazoles;
phenylureas
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
lde225sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.

sonidegib: specific Smoothened/Smo antagonist
aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activitybenzamides;
monochlorobenzenes;
pyridines;
sulfone
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamidethioureas
ipi-926IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first sourcepiperidines
robotnikininrobotnikinin: binds sonic hedgehog protein to block its signaling pathway; structure in first source
gsk 1363089GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first sourcearomatic ether
tak-441TAK-441: structure in first source
ly2940680
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylureaBGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor.

infigratinib: structure in first source
aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas
antineoplastic agent;
fibroblast growth factor receptor antagonist
cep-32496agerafenib: inhibitor of RAF family kinases; structure in first source
pf-52748571-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source